Skip to main content
Gastro Hep Advances logoLink to Gastro Hep Advances
. 2026 Jul 20;5(10):101067. doi: 10.1016/j.gastha.2026.101067

Gut Microbiota Associated With Hyperlipidemia: A Systematic Review and Meta-Analysis

Chai Xian Hua 1,∗, Hao Jeun Yap 1, David Bin-Chia Wu 2, Jonathan Wei Jie Lee 3,4,5, Chun Wie Chong 6,7, Doreen Su Yin Tan 1
PMCID: PMC13499128  PMID: 42633141

Abstract

Background and Aims

Hyperlipidemia (HLD) is a major risk factor for cardiovascular disease. Increasing evidence suggests that gut microbiota may influence lipid metabolism, although findings remain heterogeneous. We conducted a systematic review and meta-analysis to synthesize differences in gut microbiota characteristics between individuals with HLD and healthy controls and to summarize reported associations between microbial taxa and plasma lipid levels.

Methods

This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (International Prospective Register of Systematic Reviews number: CRD42024549784). PubMed, Embase, Scopus, Web of Science, Clinicaltrials.gov, Google Scholar, and Science.gov were searched for case-control or cross-sectional studies assessing gut microbiota composition in HLD. Alpha diversity was pooled as standardized mean differences, while beta diversity, taxonomic differences, and microbiota–lipid associations were synthesized qualitatively. Exploratory meta-regression analyses evaluated study-level associations between selected taxa and lipid parameters with separate adjustment for age, body mass index, and sex.

Results

Ten studies comprising 561 HLD patients and 1165 controls were included. Pooled alpha diversity indices showed no significant differences between groups, and beta diversity analyses revealed no consistent separation in overall microbial community composition. At the taxonomic level, short-chain fatty acid- and bile salt hydrolase-producing genera, including Faecalibacterium, Parabacteroides, and Roseburia, were consistently reported as less abundant in HLD. Exploratory correlation and meta-regression analyses identified heterogeneous associations between selected genera and circulating lipid parameters.

Conclusion

Current evidence does not consistently support global gut microbiota diversity as a discriminator of HLD status. However, recurrent associations involving specific microbial taxa suggest that taxon- and function-focused analyses may be more informative than diversity metrics alone. Longitudinal, interventional, and multi-omics studies are needed to clarify causality and clinical relevance.

Keywords: Gut Microbiota, Hyperlipidemia, Systematic Review, Meta-Analysis

Introduction

Hyperlipidemia (HLD) is a prevalent metabolic disorder characterized by elevated plasma levels of low-density lipoprotein (LDL), total cholesterol (TC) and/or triglyceride (TG), and reduced levels of high-density lipoprotein (HDL).1 Effective management of HLD is critical for reducing cardiovascular disease risk.2 Although pharmacological therapies such as statins, bempedoic acid, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and bile acid (BA) sequestrants remain the cornerstone of treatment, non-pharmacological strategies are increasingly recognized as important adjuncts that may enhance lipid control while limiting drug-related adverse effects.1,3

The gut microbiota, comprising a complex community of microorganisms inhabiting the gastrointestinal tract, plays key roles in energy homeostasis, immune regulation, and host metabolism.4 Growing evidence implicates the gut microbiota in lipid metabolism and cardiometabolic health.5,6 Microbial composition is shaped by multiple factors, including diet, age, body mass index (BMI), sex, geographic region, and medication use.7, 8, 9 While interventional studies have demonstrated that probiotics,10 functional foods,11 and medications12 can modulate gut microbiota and related metabolic biomarkers, less is known about the underlying microbiota characteristics associated with HLD in the absence of therapeutic intervention. Characterizing gut microbiota diversity and taxonomic patterns linked to plasma lipid levels may therefore inform biomarker discovery and therapeutic development.13

Several biological pathways have been proposed to link gut microbiota with lipid metabolism. Microbially derived short-chain fatty acids (SCFAs) can influence lipid and energy homeostasis via G-protein–coupled receptors such as GPR41 and GPR43.14,15 Gut microbial modulation of the BA pool through bile salt hydrolase (BSH) activity may alter farnesoid X receptor–fibroblast growth factor 19 signaling, thereby affecting hepatic lipid synthesis and transport.16 In addition, microbial production of trimethylamine and its hepatic conversion to trimethylamine N-oxide has been associated with HLD and cardiovascular risk.17 Alterations in intestinal barrier integrity and low-grade inflammation may further influence lipid metabolism through systemic inflammatory pathways.18 Together, these mechanisms provide a biologically plausible framework for interpreting microbiota-lipid associations.

In this study, we conducted a systematic review of observational studies comparing the gut microbiota characteristics between individuals with HLD and healthy controls. To capture the inherent diseased-associated microbiota state, we included only studies in which participants were not receiving lipid-lowering medications or dietary interventions. We synthesized evidence on differences in gut microbiota diversity and taxonomic composition and summarized reported associations between microbial taxa and plasma lipid parameters, including LDL, HDL, TC, and TG levels.

Materials and Methods

Protocol and Registration

This systematic review was performed and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement.19 This was registered on International Prospective Register of Systematic Reviews (CRD42024549784).

Literature Search Strategy

A computerized search (last update: April 30, 2025) was conducted in the following electronic databases: PubMed, EMBASE, Web of Science, Scopus, and ClinicalTrials.gov. To ensure comprehensive coverage and capture gray literature, Science.gov and Google Scholar were also searched. Google Scholar was queried on April 30, 2025, using a predefined search strategy (Supplementary Table 1), yielding 180 records; all retrieved records were screened for eligibility, and therefore no stopping rule was applied. Advanced search strategies were used for each database, incorporating combinations of controlled vocabulary (eg, Medical Subject Headings terms) and free-text keywords. Search strategies were adapted for individual databases with minimal variation.

Eligibility Criteria

Any observational study (ie, cohort, cross-sectional, and case-control) that provides the data required to identify gut microbiota characteristics for HLD patients and healthy controls was eligible.

The inclusion criteria for this study were as follows: (1) observational studies; (2) adult participants (≥18 years old); (3) studies investigating microbiota composition, diversity, and richness and plasma lipid levels as outcomes in HLD subjects; and (4) studies available in English.

The exclusion criteria were as follows: (1) animal studies; (2) interventional studies; (3) trials conducted on pregnant women or children; and (4) systematic and literature reviews, news, expert opinions, editorials, and letters. For conference abstracts, we contacted the first and/or corresponding authors for available full text.

Screening and Study Selection

After duplicates were eliminated, 2 researchers (C.X. and H.J.) independently screened the studies by title/abstract using Rayyan (https://www.rayyan.com/). Full-text screening was also performed by C.X. and H.J. while applying the inclusion/exclusion criteria. Inconsistencies on the selection procedure were resolved at a meeting between the reviewers. When consensus cannot be reached, other authors (D.T. and D.W.) were involved to solve the disagreement.

Data Extraction and Data Items

One reviewer (C.X.) extracted the data from the eligible studies using a standardized extraction form. Extracted data items included publication information, country of origin, study design, participant demographics and characteristics, classification of HLD, plasma lipid measurements, gut microbiome data, and key findings.

Synthesis

To summarize taxonomic patterns across studies, genera were considered “consistently reported” if they were described as significantly different between HLD and control groups in at least 20% of included studies. This threshold was predefined as a descriptive criterion to highlight taxa repeatedly reported across heterogeneous observational studies, rather than as a measure of statistical consistency or effect size. The pragmatic cutoff was selected to reduce emphasis on isolated single-study findings while retaining sufficient taxa for qualitative pattern synthesis given the limited number of available studies. We acknowledge that this approach may privilege commonly reported genera and should be interpreted as hypothesis-generating.

When studies reported results for multiple subgroups (eg, sex- or phenotype-specific analyses), subgroup findings were extracted separately to preserve transparency. However, these subgroup results were not treated as statistically independent evidence and were synthesized descriptively to preserve transparency and avoid obscuring potential effect modification.

Quality Assessment

Two researchers (C.X. and H.J.) evaluated the methodological quality of the included studies using the Newcastle-Ottawa Scale (NOS) to estimate risk of bias, resolving any discrepancies through discussion. NOS templates varied by study design (case-control or cross-sectional; see Supplementary Tables 1 and 2). This widely used tool evaluates observational study quality based on 8 items across 3 domains: selection, comparability (up to 2 stars), and exposure or outcome assessment. Studies were rated using a star system: 0–4 (low), 5–6 (moderate), and 7–9/10 (high) quality, with maximum scores of 9 for case-control and 10 for cross-sectional studies.20, 21, 22 In addition to the NOS, we descriptively assessed microbiome-specific methodological characteristics, including sample handling, reporting of contamination controls or batch-effect mitigation, bioinformatic pipelines, normalization strategies, beta-diversity statistical testing, multiple-testing correction, and covariate adjustment.

Statistical Analysis

Statistical analyses were conducted using STATA/MP 18.0 (StataCorp, Texas, USA). Standardized mean differences were calculated to compare alpha diversity indices (Shannon, Simpson, Faith’s phylogenetic diversity [PD], Chao1, and Ace) between HLD and control groups. For studies reporting subgroup data (eg, by sex), values were combined using Cochrane-recommended formulas.23 Phenotype-stratified meta-analyses were conducted for the Shannon index only, as this metric was reported by a sufficient number of studies to permit subgroup analysis. Due to high heterogeneity in microbiome research, a random-effects model was used. Sensitivity was assessed via leave-one-out analyses.24 Publication bias was evaluated with funnel plots and Egger’s and Begg’s tests; if detected, trim-and-fill analysis was applied. Meta-regression analyses were conducted using study-level aggregate data and were adjusted individually for age, sex, or BMI where available. Given the limited number of studies and inability to account for multiple confounders simultaneously, these analyses were considered exploratory and hypothesis-generating. When data were missing, the first and corresponding authors were contacted; if unavailable, data were extracted using WebPlotDigitizer (v5, https://automeris.io/).25

Patient and Public Involvement

Patients and/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

Results

Study Selection

The study selection process is shown in Supplementary Figure 1. Database and gray literature searches identified a large number of records, of which the majority were excluded during title and abstract screening. Full-text assessment was performed for 581 reports, with 571 excluded primarily due to unrelated disease focus, lack of plasma lipid outcomes, insufficient data to classify HLD and controls, or ineligible study design. Ten studies met all inclusion criteria and were included in the review, comprising 561 individuals with HLD and 1165 controls.26, 27, 28, 29, 30, 31, 32, 33, 34, 35

Overview of Study Characteristics

The 10 included studies were published between 2017 and 2024 and enrolled between 20 and 1141 participants. Studies were predominantly conducted in Asian populations (China, Japan, South Korea), with additional studies from Chile and Poland (Supplementary Table 2). Five studies performed subgroup analyses based on sex, lipid phenotype (eg, high vs low TC, LDL, TG, HDL), or enterotypes (eg, Bac- or Bla-type), yielding 23 study-subgroup comparisons included in descriptive synthesis.

Definition of HLD varied across studies, reflecting heterogeneity in lipid phenotypes and diagnostic criteria. Some studies defined HLD based on isolated abnormalities (eg, LDL or TC alone), whereas others used mixed dyslipidemia definitions. Diagnostic thresholds and guideline sources also differed across studies, with details summarized in Supplementary Table 2. Control groups were generally defined using inverse lipid cutoffs, although stricter definitions were applied in several studies.

Bacterial Diversity

Alpha diversity was assessed using commonly applied richness and diversity indices, including Shannon, Simpson, Chao1, Observed operational taxonomic unit/amplicon sequence variant, and Faith’s PD. Across 54 alpha diversity analyses, most comparisons reported no statistically significant differences between HLD patients and controls, with inconsistent directions among the remaining results (Figure 1). Metric selection, sequencing depth reporting, and rarefaction practices varied across studies (Supplementary Table 3).

Figure 1.

Figure 1

Alpha diversity findings across included study–subgroup comparisons in hyperlipidemia (HLD) vs controls. Each column represents an individual study or study–subgroup comparison (eg, lipid phenotype– or sex-stratified analyses). Colors denote the reported direction of alpha diversity differences relative to controls. The stacked bar summarizes the distribution of outcomes across all alpha diversity analyses.

Beta diversity was evaluated using distance-based metrics such as weighted and unweighted UniFrac, Bray–Curtis, Jaccard, and Pearson distances. Among 21 beta diversity analyses, most studies reported no significant separation between groups, and several relied primarily on ordination plots without formal statistical testing (eg, Permutational Multivariate Analysis of Variance or Analysis of Similarities) (Figure 2). Statistical testing, multiple testing correction, and covariate adjustment were inconsistently reported across studies (Supplementary Table 3). Given the absence of consistent diversity-level differences, subsequent analyses focused on taxon-level patterns and reported microbiota–lipid associations.

Figure 2.

Figure 2

Beta diversity findings across included study–subgroup comparisons in hyperlipidemia (HLD) vs controls. Each column represents a study or study–subgroup comparison. Colors indicate whether beta diversity was formally tested (eg, PERMANOVA or ANOSIM), used only for ordination, or reported as significantly different or not different between groups. The stacked bar summarizes outcomes across all beta diversity analyses. ANOSIM, Analysis of Similarities; PERMANOVA, Permutational Multivariate Analysis of Variance.

Taxonomy

Gut microbiota alterations were reported across multiple taxonomic ranks (Figure 3). At the genus level, findings were available from multiple study–subgroup comparisons derived from the 10 included studies, reflecting stratified analyses by phenotype, enterotype, or sex in several reports. Three genera, Faecalibacterium, Parabacteroides, and Roseburia, were consistently reported as significantly different between HLD patients and controls, each observed in 4 study–subgroup comparisons. Across these reports, the abundance of these genera was predominantly lower in HLD patients than in controls. These frequencies are presented descriptively to highlight repeatedly reported taxa and are not intended to represent independent confirmations or statistical consistency.

Figure 3.

Figure 3

Differentially abundant taxa across taxonomic ranks in hyperlipidemia (HLD) vs controls. Each column represents a study or study–subgroup comparison. Orange indicates higher abundance in HLD, pink indicates lower abundance, and white indicates no reported significant difference. The adjacent column summarizes the frequency of reported increases (↑) and decreases (↓) across comparisons.

Correlations Between Gut Microbiota Composition and Plasma Lipid Levels

Correlation analyses between gut microbiota and plasma lipid levels were heterogeneous in statistical approach, with most studies using Spearman correlation and fewer applying Pearson correlation (Supplementary Table 4). The majority of reported correlations were unadjusted; only a small number accounted for covariates such as age, sex, BMI, or metabolic factors (Supplementary Table 3).

Across studies, 6 genera were reported to be associated with plasma lipid parameters in at least 2 independent reports (Figure 4). TG levels were negatively correlated with Bifidobacterium and Faecalibacterium. LDL levels were positively correlated with Agathobacter. TC levels were negatively correlated with Bifidobacterium. HDL levels were positively correlated with Bacteroides and negatively correlated with Bifidobacterium.

Figure 4.

Figure 4

Reported correlations between gut microbial genera and plasma lipid parameters across studies. Only genera with correlations reported in at least 2 studies are shown. Red indicates positive correlations, blue indicates negative correlations, and gray indicates heterogeneous findings (eg, opposite directions across studies). All correlations are observational and reflect study-level associations.

Meta-Analysis of Alpha Diversity Indices

Meta-analyses were performed for Shannon, Simpson, Faith’s PD, Chao1, and Ace indices, each reported in at least 2 studies. One study assessing ileal mucosal samples was excluded from quantitative synthesis.26 No significant differences in alpha diversity were observed between HLD patients and controls across any index (Figure 5).

Figure 5.

Figure 5

Forest plots of alpha diversity. (A) Shannon index. (B) Simpson index. (C) Faith’s PD index. (D) Chao1 index. (E) Ace index.

Descriptive stratification by HLD phenotype revealed differing patterns. In hypercholesterolemia-predominant studies, alpha diversity tended to be lower in HLD patients than controls (Hedges’ g = −1.61, 95% confidence interval: −3.64–0.43; N = 2), whereas studies of mixed dyslipidemia showed no difference in alpha diversity (Hedges’ g = −0.04, 95% confidence interval: −0.41–0.32). The test for subgroup differences was not statistically significant (Q = 2.20, P = .14) (Supplementary Figure 2).

Given methodological heterogeneity, alpha diversity findings were also examined descriptively by sequencing approach and targeted 16S rRNA region. Most studies employed V3–V4 amplicon sequencing, limiting formal stratification by region. Studies using amplicon sequence variant–based pipelines and those using operational taxonomic unit–based pipelines showed similarly inconsistent alpha diversity patterns, with no sequencing approach demonstrating a consistent difference between HLD and control groups.

Publication Bias and Sensitivity Analysis

Given the small number of included studies (<10), assessments of publication bias and sensitivity analyses were inherently underpowered and should be interpreted cautiously.24,28 Funnel plots for alpha diversity were examined descriptively and did not show clear asymmetry; however, this observation does not exclude the presence of publication bias (Supplementary Figure 3). Similarly, results from Egger’s or Begg’s tests (Supplementary Table 5) should be interpreted with caution due to limited statistical power. Sensitivity analyses indicated that pooled alpha diversity estimates were not driven by any single study, as exclusion of individual studies did not materially alter results (Supplementary Figure 4). Owing to insufficient data (≤2 studies), publication bias and leave-one-out sensitivity analyses could not be performed for Faith’s PD, Chao1, and ACE indices.

Quality Assessment

Among cross-sectional studies (N = 5), all received higher NOS scores, although none justified sample size (item 2), and one did not adjust for statin use (item 5) (Supplementary Table 6). Of the 5 case-control studies, 4 received higher NOS scores and 1 received a moderate score (Supplementary Table 7). Common sources of bias across studies included case representativeness, control selection, group comparability, and unreported nonresponse rates.

While NOS scores indicated generally acceptable methodological quality according to conventional criteria, this tool does not capture key microbiome-specific sources of bias. These limitations, including sample handling, reporting of contamination controls or batch-effect mitigation, bioinformatic pipelines, normalization strategies, and statistical testing practices, were therefore assessed separately (Supplementary Table 8).

Meta-Regression Analysis of Relative Abundance of Genera and Plasma Lipid Levels

Exploratory meta-regression analyses examined study-level associations between the relative abundance of selected genera and plasma lipid parameters. Meta-regression models were adjusted separately for age, sex, or BMI (Table 1); analyses with ≤2 observations were excluded. No significant associations were observed in unadjusted or BMI-adjusted models.

Table 1.

Genera That Showed Statistical Significance When Regressed With Either Lipid Parameter, Adjusted Separately for Age, Sex, or BMI

Covariate adjusted Genus Regression coefficient, R2
LDL HDL TG TC
None None - - - -
Age Faecalibacterium −0.787, 0.58 −0.307, 0.70 −0.718, 1.00a −0.341, 0.84
Sex Agathobacter 2.139, 1.00a 0.487, 0.92 1.320, 0.98 0.614, 0.99
Bifidobacterium −0.423, 0.982 −0.112, 0.85 −0.300, 1.00a −0.107, 0.90
BMI None - - - -
a

Indicates the model that showed statistical significance (P < .05) in t-test.

In age-adjusted models, higher study-level mean relative abundance of Faecalibacterium was associated with lower mean TG levels (β = −0.718 mmol/L per 1% relative abundance increase).

In sex-adjusted models, Agathobacter abundance was positively associated with LDL levels (β = +2.139 mmol/L per 1% increase), whereas Bifidobacterium abundance was negatively associated with TG levels (β = −0.300 mmol/L per 1% relative abundance increase).

These findings reflect study-level associations derived from a small number of heterogeneous studies and should be interpreted as exploratory and hypothesis-generating rather than evidence of causal or directional effects.

Discussion

To our knowledge, this is the first systematic review and meta-analysis to examine gut microbiota alterations in HLD as a primary research question. Across 10 observational studies comprising 561 individuals with HLD and 1165 controls, we identified several genus-level microbial patterns associated with lipid abnormalities. Interpretation of these findings requires caution because included studies were predominantly cross-sectional, relied largely on 16S rRNA sequencing, and varied substantially in participant characteristics, analytical adjustment, and bioinformatic approaches. Accordingly, observed microbiota-lipid associations should be regarded as descriptive and hypothesis-generating rather than causal.

Before considering potential functional interpretations of specific taxa, it is therefore essential to examine the consistency and methodological robustness of global microbiota diversity findings across studies. Within this methodological context, we evaluated global alpha and beta diversity metrics to determine whether overall gut microbiota composition consistently differs between individuals with HLD and healthy controls.

Global Diversity Metrics and Methodological Heterogeneity

Alpha and beta diversity findings were inconsistent across studies and metrics (Figure 1, Figure 2 and Figure 1, Figure 2), suggesting that global microbiota diversity does not consistently distinguish individuals with HLD from healthy controls. This inconsistency likely reflects substantial methodological and clinical heterogeneity, including differences in sequencing, approaches, diversity metrics, statistical testing, and lipid phenotype definitions. Exploratory stratification suggested that reductions in alpha diversity may be more apparent in hypercholesterolemia-predominant populations than in mixed dyslipidemia. Importantly, diversity metrics capture compositional differences but not functional consequences; therefore, the absence of consistent diversity signals should not be interpreted as evidence that gut microbiota is unrelated to HLD.

Short-Chain Fatty Acid and Bile Salt Hydrolase-Producing Bacteria

SCFAs are key microbial metabolites involved in host lipid metabolism and intestinal immune regulation. Reduced SCFA production has been associated with impaired fatty acid oxidation, increased intestinal permeability, and chronic low-grade inflammation, all of which may contribute to HLD.36, 37, 38 In this review, several SCFA-producing genera, including Faecalibacterium, Parabacteroides, and Roseburia, were recurrently reduced in HLD. These findings are concordant with observational and interventional studies in metabolic syndrome and related metabolic disorders.39,40 However, whether these microbial alterations represent causal mediators or downstream consequences of HLD remains unclear.

Beyond SCFA production, Parabacteroides also participates in BA metabolism through BSH activity.41 Gut microbial BSHs influence BA composition, enterohepatic circulation, and host lipid signaling pathways, including farnesoid X receptor-mediated cholesterol homeostasis.42, 43, 44, 45, 46 Reduced abundance of BSH-producing taxa may therefore contribute to altered BA-lipid signaling in HLD. However, BSH effects are context-dependent, and these associations remain observational.

Microbial Taxa Associated With Lipid Parameters

Correlation and exploratory meta-regression analyses suggested associations between several genera and circulating lipid parameters. Bacteroides, a propionate-producing genus commonly associated with high-fat dietary patterns, has been linked to metabolic dysfunction and inflammatory signaling.47, 48, 49 In contrast, Bifidobacterium is frequently associated with fiber-rich diets, improved gut barrier integrity, and reduced inflammatory responses, and some strains have demonstrated lipid-lowering effects in randomized controlled trials.10,47,50, 51, 52 Together, these findings highlight the importance of microbial context and functional heterogeneity when interpreting microbiota–host metabolic interactions.

Ambiguous and Context-Dependent Microbial Associations

Associations involving Agathobacter, Anaerostipes, and Lachnoclostridium were less consistent and appeared highly context-dependent.53,54 Although these genera are linked to butyrate or acetate production, their metabolic effects may vary according to host metabolic status, dietary context, and strain-level heterogeneity.55, 56, 57, 58, 59 Lachnoclostridium has additionally been associated with trimethylamine production and adverse metabolic phenotypes, although causality remains unclear.58,60, 61, 62 Collectively, these findings suggest that microbial metabolites may exert both beneficial and detrimental effects depending on host and environmental context, underscoring the limitations of interpreting individual taxa in isolation.

Causality Framework and Implications for Microbial-Directed Therapies

Although several taxa showed reproducible associations with lipid parameters, causality cannot be inferred from the current observational literature. Establishing causal relationships will require longitudinal and interventional studies demonstrating temporality, mechanistic mediation, and reproducible responses to microbiota manipulation. Within these limitations, recurrent involvement of taxa linked to SCFA production, BA metabolism, and inflammatory signaling suggests potential relevance for future microbiota-directed therapeutic strategies.

Study Strengths and Limitations

This review synthesized current human evidence on gut microbiota alterations associated with HLD while minimizing confounding from lipid-lowering medications and dietary interventions. However, included studies were predominantly cross-sectional, geographically concentrated in Asian populations, and largely based on 16S rRNA sequencing, limiting causal inference, generalizability, and species-level interpretation. Meta-regression analyses were exploratory, relied on aggregate data, and were susceptible to ecological fallacy and residual confounding. In addition, microbiome-specific methodological heterogeneity and single-reviewer data extraction may have introduced bias.

Conclusion

This systematic review and meta-analysis synthesizes current observational evidence on gut microbiota characteristics associated with HLD. While current evidence does not demonstrate consistent differences in overall gut microbiota diversity in HLD, several genera, particularly Faecalibacterium, Parabacteroides, and Roseburia, were consistently reported as less abundant in HLD across studies. Correlation and exploratory meta-regression analyses further identified associations between selected taxa, including Bacteroides, Bifidobacterium, Agathobacter, Anaerostipes, and Lachnoclostridium, and circulating lipid parameters; however, these relationships were observational and do not establish causality or directionality.

Taken together, these findings suggest that specific microbial taxa and functional pathways related to SCFA production, BA metabolism, and host-microbe interactions may be more informative than global diversity metrics in the context of HLD. Future studies integrating longitudinal designs, interventional approaches, and multi-omics data are needed to clarify temporal relationships, mechanistic pathways, and clinical relevance. Such work will be essential before microbiota-based markers or microbial-directed strategies can be considered for translation into lipid management or cardiovascular risk reduction.

Acknowledgments

The authors would like to thank the senior librarians from NUS, Siu Chen Lim and Annelissa Chin, for their assistance during the development of the search strategy.

Footnotes

Conflicts of Interest: This author discloses the following: JWJL is a co-founder of AMILI and serves as a member of the scientific advisory board. The remaining authors disclose no conflicts.

Funding: The authors report no funding.

Ethical Statement: This is a systematic review and meta-analysis. No ethics approval is required.

Data Transparency Statement: Data are available within supplementary materials.

Reporting Guidelines: PRISMA checklist (Preferred Reporting Items for Systematic Reviews and Meta-Analyses); PROSPERO registration (CRD42024549784).

Material associated with this article can be found, in the online version, at https://doi.org/10.1016/j.gastha.2026.101067.

Supplementary Materials

Supplementary Appendix
mmc1.pdf (1.1MB, pdf)
Supplementary Dataset
mmc2.xlsx (50.4KB, xlsx)
Supplementary_NOS_Table
mmc3.xlsx (19.3KB, xlsx)
Extended PDF
mmc4.pdf (9MB, pdf)

References

  • 1.Ezeh K.J., Ezeudemba O. Hyperlipidemia: a review of the novel methods for the management of lipids. Cureus. 2021;13(7) doi: 10.7759/cureus.16412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Di Cesare M., Perel P., Taylor S., et al. The heart of the world. Glob Heart. 2024;19(1):11. doi: 10.5334/gh.1288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Yang H., Song X., Huang X., et al. Mesona chinensis benth. Extract ameliorates hyperlipidemia in high-fat diet-fed mice and rats by regulating the gut microbiota. Foods [Internet] 2024;13(21):3383. doi: 10.3390/foods13213383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mansuri N.M., Mann N.K., Rizwan S., et al. Role of gut microbiome in cardiovascular events: a systematic review. Cureus. 2022;14(12) doi: 10.7759/cureus.32465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lampe J.W., Navarro S.L., Hullar M.A.J., et al. Inter-individual differences in response to dietary intervention: integrating omics platforms towards personalised dietary recommendations. Proc Nutr Soc. 2013;72(2):207–218. doi: 10.1017/S0029665113000025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Elizabeth P.R., Adam L.H., Corey D.B., et al. Advances in nutritional metabolomics. Curr Metabolomics. 2013;1(2):109–120. doi: 10.2174/2213235x11301020001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Maqoud F., Calabrese F.M., Celano G., et al. Role of increasing body mass index in gut barrier dysfunction, systemic inflammation, and metabolic dysregulation in obesity. Nutrients. 2024;17(1):72. doi: 10.3390/nu17010072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yi C., Gao L., Zhang C., et al. Comparative analyses of gut microbiomes in Hycleus cichorii (coleoptera: meloidae) adults reveal their distinct microbes, microbial diversity and composition associated to food. Ecol Evol. 2025;15(2) doi: 10.1002/ece3.70948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Li S., Fan S., Ma Y., et al. Influence of gender, age, and body mass index on the gut microbiota of individuals from south China. Front Cell Infect Microbiol. 2024;14 doi: 10.3389/fcimb.2024.1419884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Niu X., Zhang Q., Zhang Y., et al. Effect of bifidobacterium animalis subsp. lactis langg jz-08 on lipid metabolism in individuals with obesity and dyslipidemia: a randomised, double-blind, and placebo-controlled trial. Hum Nutr Metab. 2025;40 [Google Scholar]
  • 11.Minamizuka T., Koshizaka M., Shoji M., et al. Low dose red yeast rice with monacolin k lowers ldl cholesterol and blood pressure in Japanese with mild dyslipidemia: a multicenter, randomized trial. Asia Pac J Clin Nutr. 2021;30(3):424–435. doi: 10.6133/apjcn.202109_30(3).0009. [DOI] [PubMed] [Google Scholar]
  • 12.Wu C., Zhao Y., Zhang Y., et al. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (bbr) and facilitates to predict bbr's cholesterol-decreasing efficacy in patients. J Adv Res. 2022;37:197–208. doi: 10.1016/j.jare.2021.07.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.McGuinness A.J., Davis J.A., Dawson S.L., et al. A systematic review of gut microbiota composition in observational studies of major depressive disorder, bipolar disorder and schizophrenia. Mol Psychiatry. 2022;27(4):1920–1935. doi: 10.1038/s41380-022-01456-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sankarganesh P., Bhunia A., Ganesh Kumar A., et al. Short-chain fatty acids (scfas) in gut health: implications for drug metabolism and therapeutics. Med Microecology. 2025;25 [Google Scholar]
  • 15.Zhou H., Yu B., Sun J., et al. Short-chain fatty acids can improve lipid and glucose metabolism independently of the pig gut microbiota. J Anim Sci Biotechnol. 2021;12(1):61. doi: 10.1186/s40104-021-00581-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mori H., Svegliati Baroni G., Marzioni M., et al. Farnesoid x receptor, bile acid metabolism, and gut microbiota. Metabolites. 2022;12(7):647. doi: 10.3390/metabo12070647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Liu Y., Dai M. Trimethylamine n-oxide generated by the gut microbiota is associated with vascular inflammation: new insights into atherosclerosis. Mediators Inflamm. 2020;2020 doi: 10.1155/2020/4634172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Yang-Jensen S.K., Nägele N.S., Jensen B.A.H. From gut to blood: barrier dysfunction as a driver of systemic low-grade inflammation in cardiometabolic disease. Am J Physiology-Cell Physiol. 2025;329(6):C1723–C1741. doi: 10.1152/ajpcell.00704.2025. [DOI] [PubMed] [Google Scholar]
  • 19.Moher D., Liberati A., Tetzlaff J., et al. Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. Plos Med. 2009;6(7) doi: 10.1371/journal.pmed.1000097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wells G.A., Wells G., Shea B., et al., editors. The newcastle-ottawa scale (nos) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; Ottawa: 2014. [Google Scholar]
  • 21.Mamikutty R., Aly A.S., Marhazlinda J. Selecting risk of bias tools for observational studies for a systematic review of anthropometric measurements and dental caries among children. Int J Environ Res Public Health. 2021;18(16):8623. doi: 10.3390/ijerph18168623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Viswanathan M., Ansari M.T., Berkman N.D., et al. Assessing the risk of bias of individual studies in systematic reviews of health care interventions. 2012. https://effectivehealthcare.ahrq.gov/products/methods-guidance-bias-individual-studies/methods#toc-4 [PubMed]
  • 23.Higgins J.P.T., Li T., Deeks J.J. Chapter 6: choosing effect measures and computing estimates of effect. Cochrane Handbook for Systematic Reviews of Interventions version 6.3; Cochrane: 2022. https://training.cochrane.org/handbook/archive/v6.3/chapter-06 [Google Scholar]
  • 24.Cai M., Lin L., Jiang F., et al. Gut microbiota changes in patients with hypertension: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2023;25(12):1053–1068. doi: 10.1111/jch.14722. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Cramond F., O'Mara-Eves A., Doran-Constant L., et al. The development and evaluation of an online application to assist in the extraction of data from graphs for use in systematic reviews. Wellcome Open Res. 2018;3:157. doi: 10.12688/wellcomeopenres.14738.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Li J., Ma J., Wang W., et al. Alterations of ileal mucosa-associated microbiota in hypercholesterolemia patients. Heliyon. 2023;9(12) doi: 10.1016/j.heliyon.2023.e22116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Morales C., Rojas G., Rebolledo C., et al. Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects. Front Cell Infect Microbiol. 2022;12 doi: 10.3389/fcimb.2022.943609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Qu D., Xia Y., Wang G., et al. A retrospective study of gut microbiota characteristics in a shanghai elderly cohort of hyperlipidemic patients. Food Biosci. 2024;60 [Google Scholar]
  • 29.Rebolledo C., Cuevas A., Zambrano T., et al. Bacterial community profile of the gut microbiota differs between hypercholesterolemic subjects and controls. Biomed Res Int. 2017;2017(1) doi: 10.1155/2017/8127814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Xia M., Xu Y., Li H., et al. Structural and functional alteration of the gut microbiota in elderly patients with hyperlipidemia. Front Cell Infect Microbiol. 2024;14 doi: 10.3389/fcimb.2024.1333145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Gózd-Barszczewska A., Kozioł-Montewka M., Barszczewski P., et al. Gut microbiome as a biomarker of cardiometabolic disorders. Ann Agric Environ Med. 2017;24(3):416–422. doi: 10.26444/aaem/75456. [DOI] [PubMed] [Google Scholar]
  • 32.Guo L., Wang Y.Y., Wang J.H., et al. Associations of gut microbiota with dyslipidemia based on sex differences in subjects from northwestern China. World J Gastroenterol. 2022;28(27):3455–3475. doi: 10.3748/wjg.v28.i27.3455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Miyajima Y., Karashima S., Ogai K., et al. Impact of gut microbiome on dyslipidemia in Japanese adults: assessment of the shika-machi super preventive health examination results for causal inference. Front Cell Infect Microbiol. 2022;12 doi: 10.3389/fcimb.2022.908997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Yang T., Li G., Xu Y., et al. Characterization of the gut microbiota in polycystic ovary syndrome with dyslipidemia. BMC Microbiol. 2024;24(1):169. doi: 10.1186/s12866-024-03329-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Yun K.E., Kim J., Kim M-h, et al. Major lipids, apolipoproteins, and alterations of gut microbiota. J Clin Med [Internet] 2020;9(5):1589. doi: 10.3390/jcm9051589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Iván J., Major E., Sipos A., et al. The short-chain fatty acid propionate inhibits adipogenic differentiation of human chorion-derived mesenchymal stem cells through the free fatty acid receptor 2. Stem Cells Dev. 2017;26(23):1724–1733. doi: 10.1089/scd.2017.0035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Salvi P.S., Cowles R.A. Butyrate and the intestinal epithelium: modulation of proliferation and inflammation in homeostasis and disease. Cells. 2021;10(7):1775. doi: 10.3390/cells10071775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Di Vincenzo F., Del Gaudio A., Petito V., et al. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024;19(2):275–293. doi: 10.1007/s11739-023-03374-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Moreno-Indias I., Sánchez-Alcoholado L., Pérez-Martínez P., et al. Red wine polyphenols modulate fecal microbiota and reduce markers of the metabolic syndrome in obese patients. Food Funct. 2016;7(4):1775–1787. doi: 10.1039/c5fo00886g. [DOI] [PubMed] [Google Scholar]
  • 40.Gargari G., Deon V., Taverniti V., et al. Evidence of dysbiosis in the intestinal microbial ecosystem of children and adolescents with primary hyperlipidemia and the potential role of regular hazelnut intake. FEMS Microbiol Ecol. 2018;94(5):fiy045. doi: 10.1093/femsec/fiy045. [DOI] [PubMed] [Google Scholar]
  • 41.Cui Y., Zhang L., Wang X., et al. Roles of intestinal parabacteroides in human health and diseases. FEMS Microbiol Lett. 2022;369(1):fnac072. doi: 10.1093/femsle/fnac072. [DOI] [PubMed] [Google Scholar]
  • 42.Chiang J.Y.L., Ferrell J.M. Discovery of farnesoid x receptor and its role in bile acid metabolism. Mol Cell Endocrinol. 2022;548 doi: 10.1016/j.mce.2022.111618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Peng Y.-L., Wang S.-H., Zhang Y.-L., et al. Effects of bile acids on the growth, composition and metabolism of gut bacteria. NPJ Biofilms Microbiomes. 2024;10(1):112. doi: 10.1038/s41522-024-00566-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Sirvent A., Claudel T., Martin G., et al. The farnesoid x receptor induces very low density lipoprotein receptor gene expression. FEBS Lett. 2004;566(1-3):173–177. doi: 10.1016/j.febslet.2004.04.026. [DOI] [PubMed] [Google Scholar]
  • 45.He Y., Shaoyong W., Chen Y., et al. The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity. J Adv Res. 2025;80:351–370. doi: 10.1016/j.jare.2025.05.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Xie Z., Jiang H., Liu W., et al. The triterpenoid sapogenin (2alpha-oh-protopanoxadiol) ameliorates metabolic syndrome via the intestinal fxr/glp-1 axis through gut microbiota remodelling. Cell Death Dis. 2020;11(9):770. doi: 10.1038/s41419-020-02974-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Salonen A., Lahti L., Salojärvi J., et al. Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men. ISME J. 2014;8(11):2218–2230. doi: 10.1038/ismej.2014.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wang J., Li W., Wang C., et al. Enterotype bacteroides is associated with a high risk in patients with diabetes: a pilot study. J Diabetes Res. 2020;2020 doi: 10.1155/2020/6047145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Nizigiyimana P., Xu B., Liu L., et al. Gut microbiota is associated with differential metabolic characteristics: a study on a defined cohort of africans and Chinese. Front Endocrinol. 2022;13:2022. doi: 10.3389/fendo.2022.942383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Döring C., Basen M. Propionate production by Bacteroidia gut bacteria and its dependence on substrate concentrations differs among species. Biotechnol Biofuels Bioproducts. 2024;17(1):95. doi: 10.1186/s13068-024-02539-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Al-Ishaq R.K., Samuel S.M., Büsselberg D. The influence of gut microbial species on diabetes mellitus. Int J Mol Sci. 2023;24(9):8118. doi: 10.3390/ijms24098118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Philippe D., Heupel E., Blum-Sperisen S., et al. Treatment with bifidobacterium bifidum 17 partially protects mice from th1-driven inflammation in a chemically induced model of colitis. Int J Food Microbiol. 2011;149(1):45–49. doi: 10.1016/j.ijfoodmicro.2010.12.020. [DOI] [PubMed] [Google Scholar]
  • 53.Hayashi K., Uchida R., Horiba T., et al. Soy sauce-like seasoning enhances the growth of agathobacter rectalis and the production of butyrate, propionate, and lactate. Biosci Microbiota Food Health. 2024;43(3):275–281. doi: 10.12938/bmfh.2023-103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Peng K., Dong W., Luo T., et al. Butyrate and obesity: current research status and future prospect. Front Endocrinol (Lausanne) 2023;14 doi: 10.3389/fendo.2023.1098881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.den Besten G., Lange K., Havinga R., et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am J Physiol Gastrointestinal Liver Physiol. 2013;305(12):G900–G910. doi: 10.1152/ajpgi.00265.2013. [DOI] [PubMed] [Google Scholar]
  • 56.Chen R., Zhang C., Xu F., et al. Meta-analysis reveals gut microbiome and functional pathway alterations in response to resistant starch. Food Funct. 2023;14(11):5251–5263. doi: 10.1039/d3fo00845b. [DOI] [PubMed] [Google Scholar]
  • 57.Hernández M.A.G., Canfora E.E., Jocken J.W.E., et al. The short-chain fatty acid acetate in body weight control and insulin sensitivity. Nutrients. 2019;11(8):1943. doi: 10.3390/nu11081943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Ma C., Xu C., Zheng M., et al. Utilizing lactic acid bacteria to improve hyperlipidemia: a comprehensive analysis from gut microbiota to metabolic pathways. Foods. 2024;13(24):4058. doi: 10.3390/foods13244058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Nogal A., Louca P., Zhang X., et al. Circulating levels of the short-chain fatty acid acetate mediate the effect of the gut microbiome on visceral fat. Front Microbiol. 2021;12:2021. doi: 10.3389/fmicb.2021.711359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Bhattacharjee D., Millman L.C., Seesengood M.L., et al. Genomic insights into the functional and metabolic versatility of gut microbiome Anaerostipes species. Microb Genom. 2025;11:001617. doi: 10.1099/mgen.0.001617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Wang Y., Ye X., Ding D., et al. Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes. J Int Med Res. 2020;48(9) doi: 10.1177/0300060520936806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Cai Y.-Y., Huang F.-Q., Lao X., et al. Integrated metagenomics identifies a crucial role for trimethylamine-producing lachnoclostridium in promoting atherosclerosis. NPJ Biofilms Microbiomes. 2022;8(1):11. doi: 10.1038/s41522-022-00273-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Appendix
mmc1.pdf (1.1MB, pdf)
Supplementary Dataset
mmc2.xlsx (50.4KB, xlsx)
Supplementary_NOS_Table
mmc3.xlsx (19.3KB, xlsx)
Extended PDF
mmc4.pdf (9MB, pdf)

Articles from Gastro Hep Advances are provided here courtesy of Elsevier

RESOURCES